Glowise editorial guide

CagriSema Weight-Loss Results: What the Trials Actually Show

See why CagriSema headlines cite 20.4%, 22.7% and 25.4% weight loss, what the direct tirzepatide trial found, and where FDA approval stands.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

Maya Lee

Glowise Senior GLP-1 Content Editor

Published November 19, 20265 min read
Download the Glowise App

Share this guide

Xfin
An adult reading a research summary beside a notebook at a sunlit table

In REDEFINE 1, adults without diabetes lost an estimated average 20.4% of starting weight with CagriSema at 68 weeks, compared with 3.0% with placebo. The often-quoted 22.7% came from an analysis of the same trial that estimated what would happen if participants stayed on their assigned treatment. The more recent 25.4% figure describes people who had already responded early. Each number answers a different question. CagriSema remains investigational in the U.S. as of November 20, 2026. REDEFINE 1 trial report · REDEFINE 1 early-response analysis

What is CagriSema, and what did its main weight-loss trial compare?

CagriSema combines cagrilintide, a long-acting version of a hormone that helps regulate fullness, and semaglutide, a GLP-1 receptor agonist. The combination is being studied as a weekly injection. REDEFINE 1 randomly assigned 3,417 adults with obesity or overweight with a qualifying complication, without diabetes, to CagriSema, either ingredient alone or placebo. Participants also received lifestyle support.

What participants were assignedEstimated average weight loss at 68 weeks
CagriSema20.4%
Semaglutide alone14.9%
Cagrilintide alone11.5%
Placebo3.0%

These estimates account for people stopping assigned treatment or receiving other weight-management interventions. Within the same trial, the estimates for the combination and semaglutide alone differ by 5.5 percentage points. That comparison helps show what was gained by assigning the combination in the trial. It doesn’t tell someone already taking semaglutide how much more weight they would lose if they changed treatment. REDEFINE 1 original trial

Why do the headlines say 20.4%, 22.7% and 25.4%?

  • 20.4% versus 3.0%: The main analysis estimated weight loss after assignment to CagriSema or placebo, including the effects of stopping treatment or using another weight intervention. The trial calls this the treatment-policy estimate.
  • 22.7% versus 2.3%: Another analysis estimated what would happen if participants stayed on their assigned treatment and didn’t use rescue interventions. This is a model-based estimate for the trial population.
  • 25.4%: A November 2026 analysis looked back at participants who had already lost at least 5% by week 8 while on CagriSema. The 25.4% is the observed average for those early responders at week 68. About two-thirds of CagriSema-treated participants met the early-response definition.

So if you see a headline that says “25% average weight loss,” look for who was included in the average. Selecting people based on their response after treatment began gives you a different group from everyone randomly assigned at the start. REDEFINE 1 trial methods and results · November 2026 sponsor analysis

What did researchers find in adults with type 2 diabetes?

In REDEFINE 2, 1,206 adults with type 2 diabetes and overweight or obesity were randomized to the combination or placebo for 68 weeks. The main analysis estimated 13.7% weight loss with CagriSema versus 3.4% with placebo. That’s the trial to look at when asking about this population. REDEFINE 1 had different participants and the trials were run separately, so their averages cannot establish how much of the difference was due to diabetes itself. REDEFINE 2 trial publication

Did CagriSema match tirzepatide in the direct obesity trial?

REDEFINE 4 did not reach its main goal of showing that CagriSema was close enough to tirzepatide within a prespecified margin for weight loss. In the open-label, 84-week study of 809 adults with obesity and without diabetes, the sponsor reported estimated losses of 23.0% with CagriSema versus 25.5% with tirzepatide under the adherence-based analysis. The analysis that accounted for discontinuation gave 20.2% versus 23.6%, respectively. The CagriSema group can show a substantial average reduction while the study falls short of its comparative goal. These are sponsor-reported results for the regimens tested. Novo Nordisk’s REDEFINE 4 results announcement

Do newer studies change that conclusion?

The November publication of REDEFINE 9 adds evidence about two lower-dose combinations. It enrolled 309 adults with obesity or qualifying overweight without diabetes and compared those regimens with placebo for 68 weeks. Both regimens showed greater average loss than placebo. The study did not include tirzepatide or the original higher-dose CagriSema arm. If you see the newer estimates used to rank doses or overturn the tirzepatide comparison, check who was actually randomized to what. REDEFINE 9 trial publication

Is CagriSema FDA-approved, and what’s still uncertain?

CagriSema is not FDA-approved in the United States as of November 20, 2026. Novo Nordisk filed its U.S. weight-management application in December 2025 and continued to describe the product as investigational in its November update. The FDA’s approval records checked on November 20 showed no approved CagriSema product. Novo Nordisk’s November U.S. update · FDA’s 2026 approvals

In REDEFINE 1, digestive adverse events were reported by 79.6% of people assigned CagriSema and 39.9% assigned placebo, with most events mild or moderate and transient. 5.9% versus 3.5%, respectively, stopped treatment due to adverse events. Those rates describe that study. Questions about uncommon harms and longer-term health outcomes require other evidence. A headline about weight loss alone can’t settle those questions. REDEFINE 1 safety reporting

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

About the author

Maya Lee

Glowise Senior GLP-1 Content Editor

Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.

She helps readers ask better questions and keep the details relevant to a care conversation together.

See more Glowise on Google

Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.

Glowise library

Bring your GLP-1 routine into one place.

Download the Glowise app to keep medication, meals, hydration, side effects, and progress together.